EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis and antitumor activity of 4-indazolylpyrimidine derivatives as EGFR inhibitors

Ting Yang, Xiaoling He, Ting Wu, Wenqiang Zhu, Zhiwu Long, Yi Le

Molecular Diversity · 2025

DOI: 10.1007/s11030-024-11052-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Ting Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China. Hauptthemen laut MEDLINE: ErbB Receptors, Antineoplastic Agents, Pyrimidines, Drug Design. Die Arbeit nennt 39 Literaturangaben. Gefördert von: GZU (Guizhou University) Found for Newly Enrolled Talent.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To overcome T790M mutation, a novel series of 4-indazolypyrimidine derivatives were developed as novel EGFR inhibitors employing a scaffold hopping drug design strategy. The biological activities of the target compounds were evaluated against two tumor cell lines (A431 and NCI-H1975), normal cell 2BS and EGFRT790M/L858R kinase. The results indicated that the majority of the compounds exhibited promising antitumor activity and low toxicity. Specifically, compounds 4e and 4s displayed the highest efficacy, with IC50 values of 0.55 μM and 0.47 μM, respectively. Moreover, compounds 4e and 4s demonstrated exceptional activity against EGFRT790M/L858R, with IC50 values of 12.04 and 28.79 nM. Additionally, further studies revealed that compounds 4e and 4s could induce apoptosis in NCI-H1975 cells and arrest the cells in the G2/M phase. Molecular docking studies revealed that compounds 4e and 4s could interact closely with EGFR. These findings lay the groundwork for further investigation of compounds 4e and 4s as potential EGFR inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsAntineoplastic AgentsPyrimidinesDrug DesignProtein Kinase InhibitorsIndazolesHumansCell Line, TumorMolecular Docking SimulationApoptosisStructure-Activity RelationshipCell ProliferationDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

AntitumorEGFRInhibitorNSCLCSynthesis

Substanzen

ErbB ReceptorsAntineoplastic AgentsPyrimidinesProtein Kinase InhibitorsEGFR protein, humanIndazoles

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China.
  • Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, 550025, China.
  • School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China. yile2021@163.com.
  • Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, 550025, China. yile2021@163.com.

Förderung

  • GZU (Guizhou University) Found for Newly Enrolled Talent

Zitieren

APA

Yang, T., He, X., Wu, T., Zhu, W., Long, Z., & Le, Y. (2025). Design, synthesis and antitumor activity of 4-indazolylpyrimidine derivatives as EGFR inhibitors. Molecular Diversity. https://doi.org/10.1007/s11030-024-11052-y

Vancouver

Yang T, He X, Wu T, Zhu W, Long Z, Le Y. Design, synthesis and antitumor activity of 4-indazolylpyrimidine derivatives as EGFR inhibitors. Molecular Diversity. 2025. doi:10.1007/s11030-024-11052-y

BibTeX
@article{Yang2025,
  author = {Yang, Ting and He, Xiaoling and Wu, Ting and Zhu, Wenqiang and Long, Zhiwu and Le, Yi},
  title = {Design, synthesis and antitumor activity of 4-indazolylpyrimidine derivatives as EGFR inhibitors},
  journal = {Molecular Diversity},
  year = {2025},
  doi = {10.1007/s11030-024-11052-y}
}
Kostenlos starten →